

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Topic selection and scoping

MT413 Rezum for treating benign prostatic hyperplasia

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

1. Have any potential equality issues been identified during the development of the topic briefing note or during selection, and, if so, what are they?

The risk of having a benign prostatic hyperplasia increases with age. Certain groups of men are more prone to prostate enlargement because of being overweight or underlying conditions such as diabetes. Age and disability are protected characteristics under the equality act 2010. The technology may be of particular benefit for those who wish to retain sexual function.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

No equality issues have been identified

3. Has any change to the draft scope been agreed to highlight potential equality issues?

During draft scope consultation, it was highlighted that some patients may particularly benefit from the Rezum system because they do not accept blood transfusions due to religious beliefs. The issue has been included in the special considerations section of the decision problem.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

It was also noted during scope consultation that patients who have communication difficulties due to dementia or learning disabilities, the use of local or regional anaesthesia may not be suitable for this group of patients. However, these were not considered equality issues, as the company noted that some patients would require general anaesthesia if they do not tolerate local anaesthesia.

Approved by Associate Director: Joanne Holden

Date: 04 July 2019